Key result
Pharmacological RAS inhibition significantly reduced systolic blood pressure (from 159 to 126 mmHg in hypertensive rats) and proteinuria, indicating RAS contributes to disease progression.
Why the study?
Does pharmacological RAS inhibition reduce blood pressure and proteinuria in fawn-hooded hypertensive rats?
Population
Fawn-hooded hypertensive rats and normotensive controls
Comparison
Pharmacological renin-angiotensin system… vs Untreated FHH rats and normotensive controls
Design
Preclinical
Follow-up
over the animals' lifetime
Authors
Loading...
Extends preclinical support for RAS inhibition in genetic hypertension; leaves open human translation and practice change.
Does pharmacological RAS inhibition reduce blood pressure and proteinuria in fawn-hooded hypertensive rats?
In a genetic rat model of spontaneous hypertension, RAS inhibition reduced blood pressure and proteinuria, suggesting that RAS contributes to hypertension and kidney disease progression despite no observed elevation in plasma and renal RAS levels.
Doleželová et al. (2016) studied Hypertension and kidney disease. Pharmacological RAS inhibition vs. Untreated FHH rats / normotensive controls was evaluated on Systolic blood pressure and proteinuria. Pharmacological RAS inhibition significantly reduced systolic blood pressure (from 159 to 126 mmHg in hypertensive rats) and proteinuria, indicating RAS contributes to disease progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: